A Phase 3 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 49 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 13th largest by enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 19th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 787 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 18th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2023, is one of 18 in phase 3, and was the 30th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the effects of Rimegepant to help prevent migraine.
This study is seeking for participants who:
Participants will be asked to take 1 tablet of study medicine every other calendar day. This need to be followed regardless of whether they have a migraine on that day or not. During the OLE Phase only, if a participant has a migraine on a non-scheduled dosing day, they may take 1 tablet of Rimegepant orally disintegrating tablet (ODT) as acute treatment for their migraine, if needed, with a maximum of 1 tablet of Rimegepant per calendar day. The study team will look at how each participant is doing with the study treatment during the regular visits at the study clinic.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1.Target Population: Participant has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition, including the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of rimegepant orally disintegrating tablet (ODT) EOD for 12 weeks. OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (as needed \[PRN\] dosing).
Drug: Rimegepant
DBT Phase (Weeks 1 through 12): Participants will receive a single oral dose of placebo matching to rimegepant ODT EOD for 12 weeks. OLE Phase (Weeks 13 through 24): Participants who continue to meet study entry criteria, will enter the OLE phase and receive a single oral dose of rimegepant ODT EOD for 12 weeks. If participants have a migraine on a day that they are not scheduled to dose with rimegepant, they can take one tablet of rimegepant ODT on that calendar day to treat a migraine (PRN dosing).
Drug: Rimegepant · Drug: Placebo
Rimegepant
Also known as: PF-07899801, BHV-3000
matching placebo
Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
A migraine day(MD) was defined as any calendar day participant experienced a qualified migraine headache (onset,continuation,or recurrence), per electronic diary(eDiary). A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number(no.) of md per month (m) was prorated to 28 days and derived as:OP:28\*\[total no.of MD in OP analysis period\]/(total no.of efficacy data day in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total no.of MD in m)/(total no. of efficacy data days in m),overall DBT in on-DBT efficacy analysis period:28\*(total no.of MD through m3)/(total no.of efficacy data day through m3).
Time frame: OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)
Percentage of Participants With >=50% Reduction From the OP in the Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features(unilateral location,pulsating quality \[throbbing\], moderate/severe pain intensity, aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms(nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as: OP: 28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total no .of efficacy data days through month 3).
Time frame: OP (screening of 4 weeks prior to randomization), DBT Phase (Weeks 1 to 12)
Mean Change From the OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase
A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity\[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month), overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).
Time frame: OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 4)
Mean Change From the OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase
A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).
Time frame: OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 9 to 12)
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase
MSQoL:14-item instrument validated in 3 domains:restrictive role function,preventative role function and emotional function.Role function-restrictive domain consisted of 7 items that described how migraine limits one's daily social and work-related activities.Participants were required to respond to items using a 6-point scale ranging from 1-6, where 1=none of the time,2=little bit of the time,3=some of the time,4=good bit of the time,5=most of the time and 6=all of the time.Item scores were recorded using(7-original score).Raw dimension scores for restrictive role function domain were computed as a sum of recorded item scores(7-42) and rescaled from 0-100 scale such that lowest score(0) indicated poor quality of life(QOL) and highest scores(100) indicated better QOL.Change from baseline was calculated as MSQoL role function-restrictive domain score at Week 12 of DBT phase minus MSQoL role function-restrictive domain score at baseline.Data collected on Day 1 was referred to Baseline.
Time frame: Baseline, DBT phase (Week 12)
Mean Number of Acute Migraine Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (triptan). Acute migraine medication days were defined as either acute migraine-specific medication day or migraine day with "yes" response to the question about taking other medications to treat headache or aura. The number of migraine day per month was prorated to 28 days and derived as: OP: 28\*\[total number of migraine day in the OP analysis period\]/(total number of efficacy data days in the OP analysis period), monthly (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of migraine day in the month)/(total number of efficacy data days in the month), overall DBT in the on-DBT efficacy analysis period: 28\*(total number of migraine day through month 3)/(total number of efficacy data days through month 3).
Time frame: DBT phase (Weeks 1 to 12)
Number of Participants With Any On-Treatment Adverse Events (AEs) by Severity During the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the common terminology criteria for adverse events (CTCAE) as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Serious Adverse Events (SAEs) On-Treatment During the DBT Phase
An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With AEs Leading to Study Intervention Discontinuation During the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the DBT phase were reported.
Time frame: DBT phase: maximum of 12 weeks
Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the DBT Phase
Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], albumin, bilirubin, creatine kinase \[CK\], calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and estimated glomerular filtration rate \[eGFR\] modification of diet in renal disease \[MDRD\]) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Any On-Treatment AEs by Severity During the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the CTCAE as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With SAEs On-Treatment During the OLE Phase
An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With AEs Leading to Study Intervention Discontinuation on Treatment During the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the OLE phase were reported.
Time frame: OLE phase: maximum of 12 weeks
Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Test Abnormalities During the OLE Phase
Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (ALP, ALT, AST, albumin, bilirubin, CK, calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and eGFR MDRD) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With ALT or AST Elevations >3* Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) Elevations >2*ULN On-Treatment During the DBT Phase
Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in DBT phase were reported in this outcome measure.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With ALT or AST Elevations >3*ULN Concurrent With TBL Elevations >2*ULN On-Treatment During the OLE Phase
Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in OLE phase were reported in this outcome measure.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Hepatic-related AEs On-Treatment During the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the DBT phase were reported.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Hepatic-related AEs Leading to Study Intervention Discontinuation On-Treatment During the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the DBT phase were reported.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Hepatic-related AEs On-Treatment During the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the OLE phase were reported.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
Number of Participants With Hepatic-Related AEs Leading to Study Intervention Discontinuation On-Treatment During the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the OLE phase were reported.
Time frame: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks)
| Milestone | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Started | 393 | 394 |
| Dbt safety analysis set | 392 | 394 |
| Completed | 366 | 370 |
| Not completed | 27 | 24 |
| Withdrew: Randomized but not treated | 1 | 0 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Pregnancy | 4 | 5 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 15 | 8 |
| Withdrew: No longer met eligibility criteria | 4 | 3 |
| Withdrew: Other | 0 | 4 |
| Milestone | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Started | 360 | 364 |
| Completed | 350 | 354 |
| Not completed | 10 | 10 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 8 |
| Withdrew: Other | 3 | 1 |
| Milestone | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Started | 376 | 369 |
| Completed | 365 | 364 |
| Not completed | 11 | 5 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Pregnancy | 1 | 1 |
| Withdrew: Withdrawal by subject | 7 | 3 |
| Withdrew: Other | 2 | 0 |
A migraine day(MD) was defined as any calendar day participant experienced a qualified migraine headache (onset,continuation,or recurrence), per electronic diary(eDiary). A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number(no.) of md per month (m) was prorated to 28 days and derived as:OP:28\*\[total no.of MD in OP analysis period\]/(total no.of efficacy data day in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total no.of MD in m)/(total no. of efficacy data days in m),overall DBT in on-DBT efficacy analysis period:28\*(total no.of MD through m3)/(total no.of efficacy data day through m3).
| Migraine days per month | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | -3.64 ± 0.14 | -2.63 ± 0.14 |
A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features(unilateral location,pulsating quality \[throbbing\], moderate/severe pain intensity, aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms(nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as: OP: 28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total no .of efficacy data days through month 3).
| Percentage of participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Percentage of Participants With >=50% Reduction From the OP in the Number of Moderate to Severe Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | 55.0 (50.08 to 59.99) | 38.4 (33.56 to 43.24) |
A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity\[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month), overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).
| Migraine days per month | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Mean Change From the OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase | -2.92 ± 0.17 | -1.92 ± 0.15 |
A MD was defined as any calendar day participant experienced a qualified migraine headache(onset,continuation,or recurrence),per eDiary. A qualified migraine headache was defined as a migraine with/without aura,lasted for \>=30 minutes with \>=2 pain features (unilateral location,pulsating quality\[throbbing\],moderate/severe pain intensity,aggravated by or caused avoidance of routine physical activity \[e.g. walking/climbing stairs\]) and/or with \>=1 of the following associated symptoms (nausea and/or vomiting, both photophobia and phonophobia).The number of MD per month was prorated to 28 days and derived as:OP:28\*\[total number of MD in OP analysis period\]/(total number of efficacy data days in OP analysis period), monthly (4-week interval) on-DBT efficacy analysis period: 28\*(total number of MD in month)/(total number of efficacy data days in month),overall DBT in on-DBT efficacy analysis period:28\*(total number of MD through month 3)/(total number of efficacy data days through month 3).
| Migraine days per month | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Mean Change From the OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase | -4.19 ± 0.16 | -3.11 ± 0.17 |
MSQoL:14-item instrument validated in 3 domains:restrictive role function,preventative role function and emotional function.Role function-restrictive domain consisted of 7 items that described how migraine limits one's daily social and work-related activities.Participants were required to respond to items using a 6-point scale ranging from 1-6, where 1=none of the time,2=little bit of the time,3=some of the time,4=good bit of the time,5=most of the time and 6=all of the time.Item scores were recorded using(7-original score).Raw dimension scores for restrictive role function domain were computed as a sum of recorded item scores(7-42) and rescaled from 0-100 scale such that lowest score(0) indicated poor quality of life(QOL) and highest scores(100) indicated better QOL.Change from baseline was calculated as MSQoL role function-restrictive domain score at Week 12 of DBT phase minus MSQoL role function-restrictive domain score at baseline.Data collected on Day 1 was referred to Baseline.
| Score on a scale | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase | 14.2 ± 0.72 | 9.9 ± 0.68 |
Acute migraine-specific medication day was defined as any calendar day during which the participant took a migraine-specific medication (triptan). Acute migraine medication days were defined as either acute migraine-specific medication day or migraine day with "yes" response to the question about taking other medications to treat headache or aura. The number of migraine day per month was prorated to 28 days and derived as: OP: 28\*\[total number of migraine day in the OP analysis period\]/(total number of efficacy data days in the OP analysis period), monthly (i.e., 4-week interval) in the on-DBT efficacy analysis period: 28\*(total number of migraine day in the month)/(total number of efficacy data days in the month), overall DBT in the on-DBT efficacy analysis period: 28\*(total number of migraine day through month 3)/(total number of efficacy data days through month 3).
| Acute migraine medication days per month | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Mean Number of Acute Migraine Medication Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | 2.29 ± 0.14 | 3.18 ± 0.16 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the common terminology criteria for adverse events (CTCAE) as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.
| Participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Number of Participants With Any On-Treatment Adverse Events (AEs) by Severity During the DBT Phase | 18 | 7 |
An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.
| Participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) On-Treatment During the DBT Phase | 8 | 3 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the DBT phase were reported.
| Participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Number of Participants With AEs Leading to Study Intervention Discontinuation During the DBT Phase | 2 | 0 |
Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], albumin, bilirubin, creatine kinase \[CK\], calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and estimated glomerular filtration rate \[eGFR\] modification of diet in renal disease \[MDRD\]) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.
| Participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Lymphocytes, low | 1 | 1 |
| Neutrophils | 1 | 1 |
| ALT | 1 | 0 |
| AST | 1 | 0 |
| CK | 4 | 3 |
| Glucose, low | 1 | 0 |
| LDL cholesterol | 2 | 0 |
| Sodium, low | 1 | 0 |
| Triglycerides | 1 | 3 |
| Urine glucose | 1 | 0 |
| Urine protein | 0 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AEs were graded per the CTCAE as grade 1 indicates mild AE, grade 2 indicates moderate AE, grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention, and grade 5 indicates death related to AE. Number of participants who had grade 3 or 4 AEs were reported in this outcome measure.
| Participants | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Number of Participants With Any On-Treatment AEs by Severity During the OLE Phase | 4 | 4 |
An SAE was any event that met any of the criteria: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant were considered an important medical event.
| Participants | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Number of Participants With SAEs On-Treatment During the OLE Phase | 5 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with AEs leading to discontinuation of study intervention during the OLE phase were reported.
| Participants | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Number of Participants With AEs Leading to Study Intervention Discontinuation on Treatment During the OLE Phase | 0 | 0 |
Laboratory test included hematology (hemoglobin, lymphocytes, white blood cell count \[high, low\], neutrophils and platelets), serum chemistry (ALP, ALT, AST, albumin, bilirubin, CK, calcium \[high, low\], glucose fasting and non-fasting \[high, low\], cholesterol \[total\], glucose \[low\], creatinine, LDL cholesterol, potassium, sodium \[high, low\], triglycerides, uric acid \[urate\] and eGFR MDRD) and urinalysis (urine glucose and urine protein). Laboratory abnormalities were graded according to CTCAE as grade 3 indicates severe AE, grade 4 indicates life-threatening consequences and urgent intervention. Number of participants who had non-zero grade 3 to 4 laboratory test abnormalities were reported in this outcome measure.
| Participants | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Lymphocytes, low | 1 | 0 |
| Neutrophils | 1 | 2 |
| White blood cell count, low | 0 | 1 |
| LDL cholesterol | 2 | 4 |
| Sodium, high | 0 | 1 |
| Triglycerides | 3 | 4 |
| Urine glucose | 0 | 3 |
Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in DBT phase were reported in this outcome measure.
| Participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Number of Participants With ALT or AST Elevations >3* Upper Limit of Normal (ULN) Concurrent With Total Bilirubin (TBL) Elevations >2*ULN On-Treatment During the DBT Phase | 0 | 0 |
Number of participants with ALT or AST elevations \>3\*ULN concurrent with TBL elevations \>2\*ULN in OLE phase were reported in this outcome measure.
| Participants | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Number of Participants With ALT or AST Elevations >3*ULN Concurrent With TBL Elevations >2*ULN On-Treatment During the OLE Phase | 0 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the DBT phase were reported.
| Participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Number of Participants With Hepatic-related AEs On-Treatment During the DBT Phase | 26 | 25 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the DBT phase were reported.
| Participants | DBT Rimegepant | DBT Placebo |
|---|---|---|
| Number of Participants With Hepatic-related AEs Leading to Study Intervention Discontinuation On-Treatment During the DBT Phase | 1 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs during the OLE phase were reported.
| Participants | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Number of Participants With Hepatic-related AEs On-Treatment During the OLE Phase | 21 | 14 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with this treatment. In this outcome measure participants with hepatic-related AEs leading to discontinuation of study intervention during the OLE phase were reported.
| Participants | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant |
|---|---|---|
| Number of Participants With Hepatic-Related AEs Leading to Study Intervention Discontinuation On-Treatment During the OLE Phase | 0 | 0 |
Collected over DBT Phase: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks); OLE Phase: From Day 1 up to 4 weeks post last dose (maximum up to 16 weeks); Follow-up phase: 4 weeks after DBT Phase or completion of the OLE phase. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBT Rimegepant | 0/392 (0%) | 8/392 (2%) | 162/392 (41.3%) |
| DBT Placebo | 0/394 (0%) | 3/394 (0.8%) | 161/394 (40.9%) |
| DBT Rimegepant/ OLE Rimegepant | 0/360 (0%) | 5/360 (1.4%) | 118/360 (32.8%) |
| DBT Placebo/ OLE Rimegepant | 0/364 (0%) | 1/364 (0.3%) | 110/364 (30.2%) |
| DBT/OLE Rimegepant | 0/392 (0%) | 13/392 (3.3%) | 235/392 (59.9%) |
| Follow-up: Rimegepant | 0/376 (0%) | 3/376 (0.8%) | 10/376 (2.7%) |
| Follow-up: DBT Placebo | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Follow-up: DBT Placebo/OLE Rimegepant | 0/353 (0%) | 1/353 (0.3%) | 4/353 (1.1%) |
| Event | DBT Rimegepant | DBT Placebo | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant | DBT/OLE Rimegepant | Follow-up: Rimegepant | Follow-up: DBT Placebo | Follow-up: DBT Placebo/OLE Rimegepant |
|---|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/392 | 0/394 | 0/360 | 0/364 | 0/392 | 0/376 | 0/16 | 1/353 |
| Arteriosclerosis coronary arteryCardiac disorders | 0/392 | 0/394 | 1/360 | 0/364 | 1/392 | 0/376 | 0/16 | 0/353 |
| Tooth impactedGastrointestinal disorders | 0/392 | 0/394 | 1/360 | 0/364 | 1/392 | 0/376 | 0/16 | 0/353 |
| Drug hypersensitivityImmune system disorders | 0/392 | 0/394 | 1/360 | 0/364 | 1/392 | 0/376 | 0/16 | 0/353 |
| AppendicitisInfections and infestations | 0/392 | 0/394 | 1/360 | 0/364 | 1/392 | 0/376 | 0/16 | 0/353 |
| Joint injuryInjury, poisoning and procedural complications | 0/392 | 0/394 | 1/360 | 0/364 | 1/392 | 1/376 | 0/16 | 0/353 |
| Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/392 | 0/394 | 1/360 | 0/364 | 1/392 | 0/376 | 0/16 | 0/353 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/392 | 0/394 | 0/360 | 1/364 | 0/392 | 0/376 | 0/16 | 0/353 |
| GastritisGastrointestinal disorders | 1/392 | 0/394 | 0/360 | 0/364 | 1/392 | 1/376 | 0/16 | 0/353 |
| Gastrointestinal mucosal disorderGastrointestinal disorders | 0/392 | 0/394 | 0/360 | 0/364 | 0/392 | 1/376 | 0/16 | 0/353 |
| Event | DBT Rimegepant | DBT Placebo | DBT Rimegepant/ OLE Rimegepant | DBT Placebo/ OLE Rimegepant | DBT/OLE Rimegepant | Follow-up: Rimegepant | Follow-up: DBT Placebo | Follow-up: DBT Placebo/OLE Rimegepant |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 48/392 | 51/394 | 39/360 | 25/364 | 79/392 | 6/376 | 0/16 | 4/353 |
| Protein urine presentInvestigations | 20/392 | 14/394 | 7/360 | 14/364 | 26/392 | 0/376 | 0/16 | 0/353 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/392 | 0/394 | 0/360 | 0/364 | 0/392 | 0/376 | 1/16 | 0/353 |
| ProteinuriaRenal and urinary disorders | 6/392 | 19/394 | 6/360 | 5/364 | 11/392 | 0/376 | 0/16 | 0/353 |
| Urinary tract infectionInfections and infestations | 15/392 | 5/394 | 4/360 | 6/364 | 18/392 | 0/376 | 0/16 | 0/353 |
| PyrexiaGeneral disorders | 9/392 | 5/394 | 8/360 | 5/364 | 16/392 | 0/376 | 0/16 | 0/353 |
| InfluenzaInfections and infestations | 8/392 | 9/394 | 8/360 | 0/364 | 16/392 | 0/376 | 0/16 | 0/353 |
| NasopharyngitisInfections and infestations | 11/392 | 11/394 | 4/360 | 7/364 | 15/392 | 0/376 | 0/16 | 0/353 |
| Alanine aminotransferase increasedInvestigations | 11/392 | 12/394 | 5/360 | 4/364 | 15/392 | 0/376 | 0/16 | 0/353 |
| Blood creatine phosphokinase increasedInvestigations | 11/392 | 5/394 | 2/360 | 5/364 | 13/392 | 0/376 | 0/16 | 0/353 |
DBT safety set included participants in the enrolled analysis set who took \>=1 dose of double-blind study intervention (rimegepant or placebo).
| Age, Continuous(Years) | DBT Rimegepant | DBT Placebo | Total |
|---|---|---|---|
| Mean | 37.5 ± 9.34 | 36.9 ± 9.32 | 37.2 ± 9.33 |
| Sex: Female, Male(Participants) | DBT Rimegepant | DBT Placebo | Total |
|---|---|---|---|
| Female | 272 | 299 | 571 |
| Male | 120 | 95 | 215 |
| Ethnicity (NIH/OMB)(Participants) | DBT Rimegepant | DBT Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 392 | 394 | 786 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DBT Rimegepant | DBT Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 392 | 394 | 786 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2023 to primary completion in Aug 2025, 27 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 27 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant